

## Correction

Clinical Pharmacology  
in Drug Development  
2020, 9(6) 774  
© 2020, The American College of  
Clinical Pharmacology  
DOI: 10.1002/cpdd.854

Bergese SD, Melson T, Candiotti KA, Ayad SS, Mack RJ, McCallum SW, Du W, Gomez A, Marcet JE. A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery. *Clin Pharmacol Drug Dev.* 2019 Feb 20.; Publish Ahead of Print: <https://doi.org/10.1002/cpdd.666>.

In regards to the published paper entitled, “A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery,” a correction needs to be noted on page 22, Table 1. Referring to “time (hours) from end of surgery to first dose, mean  $\pm$  SD,” the number was previously 12.5 but has been changed to 1.25 due to a typographical error.